U.S. Markets open in 2 hrs 7 mins

Sorrento Therapeutics, Inc. (SRNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.60-0.07 (-0.81%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.67
Open8.56
BidN/A x N/A
AskN/A x N/A
Day's Range8.39 - 8.80
52 Week Range4.76 - 19.39
Volume6,366,843
Avg. VolumeN/A
Market Cap2.457B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.30
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
  • 7 High-Risk, High-Reward Stocks to Buy If You Have an Iron-Clad Stomach
    InvestorPlace

    7 High-Risk, High-Reward Stocks to Buy If You Have an Iron-Clad Stomach

    With so much enthusiasm baked into the equities sector, many investors undoubtedly feel that now is a time to consider a risk-off profile. Frankly, I agree with these folks. That said, we’re coming off the (hopefully) worst of the novel coronavirus pandemic. Therefore, others believe that the best days are still ahead of us. If you fall into this camp, you may want to dive into high-risk, high-reward stocks. To be 100% clear from the get-go, I’m not endorsing any of the following speculative sto

  • Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday
    Motley Fool

    Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

    The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.

  • Sorrento Teams with Mayo Clinic and Gets UK Approval for Phase 2 Trial for COVI-DROPS; Shares Roar 5%
    SmarterAnalyst

    Sorrento Teams with Mayo Clinic and Gets UK Approval for Phase 2 Trial for COVI-DROPS; Shares Roar 5%

    Shares of the biopharmaceutical company Sorrento Therapeutics (SRNE) jumped 5.1% in Friday’s extended trading session after the company inked a research collaboration agreement with Mayo Clinic. The company also received U.K. authorization for its Phase 2 Trial for its COVI-DROPS candidate in newly diagnosed SARS-CoV-2 infected patients. Per the agreement with Mayo Clinic, the research will involve human proof of concept studies of the Sofusa Lymphatic Drug Delivery System technology across a ra